Hope for stage IV patients

At LifeBridge Innovations our patented LB10000 device is built from the ground up for late-stage cancer patients and is specifically designed to treat metastatic disease in two or more locations on the body at once. Future patients undergoing treatment for metastatic cancer via our Adaptive Tumor Treating Fields (ATTF) platform will not be left with the painful decision of what cancer to treat and which to let grow. 

 

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

OUR SOLUTION

Our patented programmable disc system achieves dynamic reassignment of array elements to disrupt cancer cell growth.     

LEARN MORE→

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

THE SCIENCE

Alternating electric fields tug on charged mitotic proteins, derailing the machinery that tumor cells need to divide properly.​ 

LEARN MORE→

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

ABOUT

We started by trying to save one life and discovered the potential to impact millions. 

LEARN MORE→

LifeBridge Innovations’ dynamic delivery of TTF provides the capability to treat cancer in multiple locations in the body simultaneously, allowing us to offer TTF to Stage IV patients who would otherwise have few options left.​

​

Cancer remains one of the world’s leading causes of death, with millions of new cases diagnosed each year. In the U.S. alone, over 1,600 people lose their lives to cancer daily. For many patients, current treatments—surgery, chemotherapy, and radiation—can eventually fail, especially in advanced stages when the disease becomes recurrent and treatment-resistant. Tumor Treating Fields(TTF) have emerged as a promising treatment modality in cancer care. First introduced by Novocure, TTF has been recognized as a standard of care for glioblastoma by the National Comprehensive Cancer Network. However, current static TTF systems are designed to treat tumors in a single location and are limited in their ability to address diffuse metastatic disease. At LifeBridge Innovations, we are advancing the next generation of TTF therapy through our dynamic, programmable LB10000 system. Unlike static delivery, our adaptive platform is designed to target multiple areas of the body simultaneously—offering new hope for Stage IV patients with widespread metastatic disease.​